Amber Therapeutics

London, UKFounded 202111–50 employeesamber-tx.comLinkedIn

Neuromodulation

Amber Therapeutics is a medical technology company developing adaptive neuromodulation therapies for women with mixed urinary incontinence. Its first therapy, Amber UI, uses a fully implantable system targeting the pudendal nerve to sense physiological responses and dynamically adjust stimulation.

Visit amber-tx.com ↗

Founded: 2021
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

Amber Therapeutics reached several important milestones between 2023 and 2026. On Sep 5, 2023, it acquired Bioinduction, expanding its corporate and technology base in bioelectrical medicine. Its 2024 Series A brought in approximately $101.8 million, led by New Enterprise Associates, with participation from 8VC, Oxford Science Enterprises, F-Prime, Lightstone Ventures, Intuitive Ventures and other investors. A 2024 clinical report on the company’s bioelectrical device described strong effectiveness in mixed urinary incontinence, while the AURA-2 first-in-human program generated evidence on safety, surgical feasibility, pilot efficacy, quality of life and integrated sensing. On Jul 7, 2025, co-founder Tim Denison joined ONWARD Medical’s board, extending his role in the wider neurotechnology field. Investor Caroline Gaynor was named chair of the Irish Venture Capital Association on Aug 20, 2025.

Market position

Amber Therapeutics operates at the intersection of implantable medical devices, bioelectronic medicine and women’s pelvic health. Its initial focus is mixed urinary incontinence, a clinically complex condition in which urge and stress symptoms coexist. The company differentiates its approach through a fully implantable pudendal-nerve system that combines stimulation with physiological sensing and adaptive algorithms, rather than relying only on fixed stimulation settings. The Picostim System and Picostim DyNeuMo platform give Amber a more specific product identity than a general neuromodulation developer. The company’s approximately $101.8 million Series A, backed by New Enterprise Associates, 8VC, Oxford Science Enterprises, F-Prime, Lightstone Ventures and Intuitive Ventures, is substantial for a company founded in 2021. ONWARD Medical is an adjacent neurotechnology reference point through Tim Denison’s board role, but it should not be treated as a confirmed direct competitor. Comparisons with established continence and neuromodulation-device companies require additional evidence.

Growth & opportunities

Amber Therapeutics shows a progression from early company formation to clinical development and scaled financing. Founded in 2021, it received a $1.3 million Innovate UK grant on Nov 29, 2022, followed by a seed round announced on Jan 24, 2023 with 8VC and Oxford Science Enterprises as lead investors. The Sep 5, 2023 acquisition of Bioinduction was an early strategic inflection point, potentially adding capabilities as Amber developed its neuromodulation platform. The largest financing milestone was the Jun 9, 2024 Series A, which raised approximately $101.8 million and included six investors. Clinical progress has centered on AURA-2 first-in-human work and the Picostim System, with reported evidence covering safety, surgical feasibility, pilot efficacy, quality of life and integrated sensing. The Mar 19, 2026 Future Fifty non-equity assistance award indicates continued institutional support, but its value is undisclosed.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Amber Therapeutics distinct

reccy insights

What makes Amber Therapeutics distinct

01Developing a single therapy designed to address both urge and stress urinary incontinence.
02Uses adaptive, personalized neuromodulation that can dynamically respond to physiological events.
03AURA-2 first-in-human results demonstrated safety, surgical feasibility, pilot efficacy, quality-of-life improvements and the utility of integrated sensing algorithms.
04Founded and led by specialists in neuromodulation, urology, pelvic health, medical devices and clinical research.
05Backed by healthcare and technology investors including New Enterprise Associates, F-Prime, Lightstone Ventures, Oxford Science Enterprises, Intuitive Ventures and 8VC.

Technology & products

Picostim System
A fully implantable neuromodulation device that stimulates and senses the pudendal nerve to treat mixed urinary incontinence in women.

Picostim System
Personalized Adaptive Pudendal Neuromodulation
Fully implantable neuromodulation device targeting the pudendal nerve
Integrated physiological sensing
Patient-controlled adaptive algorithms
Picostim DyNeuMo closed-loop neuromodulation platform

Similar companies

Show all 6 companies

About Amber Therapeutics

Products: Picostim System
Leadership: Tim Denison, Co-Founder, Director, and Chief Engineer
Focus areas: Medical Devices, neuromodulation, women's health, urinary incontinence, pelvic health, implantable devices, bioelectronic medicine, clinical research
Headquarters: London, UK
Founded: 2021
Employees: 11–50
Patents granted: 5 (Crunchbase)
Trademarks: 1